Clinical Trials

Roche’s TECENTRIQ plus chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer: Phase III IMpower131 study

23rd March 2018

Roche announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the...

GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus

by Content Team

23rd March 2018

GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus

GSK announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with...

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

by Content Team

22nd March 2018

Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body...

Urgo Medical: The Clinical Trial EXPLORER is the First Study to Demonstrate the Efficacy of a Dressing (Urgostart®) in Diabetic Foot Ulcer Healing

by Content Team

22nd March 2018

UrgoStart® heals 60% more patients compared to a well-managed standard treatment, and reduces healing time by 60 days (compared to...

Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease

by Content Team

22nd March 2018

Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved...

Chinese researchers report first lung stem cell transplantation clinical trial

by Content Team

13th February 2018

A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first...

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease

by Content Team

10th February 2018

Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and...

Optimismm of POMALYST omit positive results for treating a malicious disease: Celegne corporation

by Content Team

9th February 2018

SMM evaluated the efficacy and safety of POMALYST/IMNOVID (pomalidomide) plus bortezomib and low-dose dexamethasone (PVd) versus bortezomib and low-dose dexamethasone...

Roche’s TECENTRIQ®and Avastin® reduced the risk of disease worsening or death by 26 percent in certain advanced kidney cancer cases

by Content Team

9th February 2018

Roche announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment...